Vertical Cytomegalovirus Transmission From HIV-Infected Women Randomized to Formula-Feed or Breastfeed Their Infants

listen audio

Study Justification:
– The study aimed to assess the effect of breastfeeding on the acquisition of cytomegalovirus (CMV) among infants delivered by HIV-infected mothers.
– CMV is associated with morbidity and mortality in HIV-exposed infants, so preventing CMV acquisition is important.
– The study provides valuable information on the relative contribution of breastfeeding to CMV infection in this population.
Study Highlights:
– The study included 138 breastfed and 134 formula-fed infants.
– Breastfed infants acquired CMV earlier and had a higher 1-year probability of CMV infection compared to formula-fed infants.
– Breastfeeding was associated with a 1.6-fold increased risk of infant CMV acquisition, independent of infant HIV status.
– Approximately one third of CMV infections occurred during the peripartum period, with 40% acquired through breastfeeding and the remainder acquired through other modes.
Recommendations for Lay Reader:
– Preventing CMV acquisition is important for HIV-exposed infants.
– Approaches that reduce CMV reactivation in mothers may help delay infant infection.
– Breastfeeding carries a higher risk of CMV acquisition compared to formula feeding.
Recommendations for Policy Maker:
– Prioritize interventions to prevent CMV acquisition in HIV-exposed infants.
– Support research and programs that aim to reduce maternal cervical and breast milk CMV reactivation.
– Provide resources and education to promote safe feeding practices for HIV-infected mothers.
Key Role Players:
– Researchers and scientists involved in CMV and HIV transmission studies.
– Healthcare professionals and clinicians working with HIV-infected mothers and infants.
– Policy makers and government officials responsible for public health programs.
Cost Items for Planning Recommendations:
– Research funding for studies on CMV prevention and interventions.
– Resources for education and training programs for healthcare professionals.
– Development and distribution of educational materials for HIV-infected mothers.
– Support for implementing safe feeding practices, such as providing formula and safe formula preparation demonstrations.
– Monitoring and evaluation of interventions to assess their effectiveness and impact.

Background. Cytomegalovirus (CMV) is associated with morbidity and mortality in human immunodeficiency virus (HIV)-exposed infants. We assessed the effect of and relative contribution of breastfeeding to CMV acquisition among infants delivered by HIV-infected mothers. Methods. Between 1993 and 1998 pregnant, HIV-infected women in Nairobi, Kenya, were randomly assigned to breastfeed or formula-feed their infants in an HIV transmission study. Women were allocated equally between treatment arms, and the study was not blinded. The primary endpoint of this nested study was time to infant CMV infection. Results. CMV infection was assessed in 138 breastfed and 134 formula-fed infants. Baseline characteristics were similar between arms. Breastfed infants acquired CMV earlier than formula-fed infants (median age of acquisition, 4.26 vs 9.87 months; P <. 001) and had a higher 1-year probability of CMV infection (0.89 vs 0.69; P <. 001). Breastfeeding was associated with a 1.6-fold increased risk of infant CMV acquisition independent of infant HIV status (multivariable hazard ratio, 1.61; 95% confidence interval, 1.20-2.16; P =. 002). Approximately one third of CMV infections occurred during the peripartum period, with 40% acquired through breastfeeding and the remainder acquired through modes other than breast milk. Conclusions. Preventing CMV acquisition may be a priority for HIV-exposed infants, but there is a narrow window of opportunity for intervention. Approaches that reduce maternal cervical and breast milk CMV reactivation may help delay infant infection.

The study was approved by the Institutional Review Board of the University of Washington and the Ethics and Research Committee of Kenyatta National Hospital. All participants provided written informed consent for participation, and human experimentation guidelines of the University of Washington were followed. This is a retrospective analysis of specimens collected during a randomized controlled trial of breastfeeding versus formula feeding and HIV transmission, conducted in Nairobi, Kenya, between 1993 and 1998 [22]. We assumed the rate of CMV acquisition in the breastfeeding arm would be similar to that in our previous observational study in Kenya, which was 90% by 6 months of age [9]. With equal allocation to study arms and estimating 300 infants would meet eligibility criteria, the study was powered to detect a 30% difference in transmission between arms, using Cox regression with β = 0.80 and α = 0.05, assuming a 2-sided test. Eligibility criteria for the randomized controlled trial included pregnancy of 2 years. For the purpose of this substudy, we included all infants who had dried blood spot (DBS) specimens collected before 14 weeks of age. This trial was conducted before antiretroviral therapy (ART) for prevention of mother-to-child HIV transmission (PMTCT) became available in Kenya; all women and infants were ART naive. At enrollment, caregivers provided sociodemographic characteristics and medical histories and underwent a clinical examination. At approximately week 32 of gestation, women were randomly assigned to the breastfeeding or formula-feeding arm at a 1:1 ratio, using computer-generated block randomization. Treatment allocation was not blinded to study staff; assignment to study arm was revealed to women and clinicians via presealed envelopes. In the formula group, safe formula preparation was demonstrated during home visits, and women were provided with free dried milk formula throughout the study. Women and infants were assessed in clinic monthly in the first year and quarterly during the second year of the infant’s life and as needed for illness. Postnatal visits included assessment of both mother’s and baby’s clinical status, as well as infant growth and feeding. Infant blood specimens were collected at birth, at 6 weeks of age, at 14 weeks of age, and every 3 months thereafter until 24 months of age for HIV testing [22]. Women delivering at home or another facility were asked to bring their newborns to the study clinic for clinical examination and HIV testing as soon as possible following delivery. Infant HIV diagnosis was conducted in this study using polymerase chain reaction (PCR) to detect HIV gag DNA in peripheral blood mononuclear cells or DBS as previously described [22, 23]. Due to the high incidence of infant HIV infection in the breast fed arm, in April 1998 the data safety and monitoring board (DSMB) closed the study early, and recommended that breast feeding women be advised to stop breast feeding and be given formula [22]. All CMV loads were measured in DBS as previously described [21]; plasma specimens from this study have been extensively used in vertical transmission studies over the past decade and were no longer were available for longitudinal CMV assessments. In our assay, when CMV loads are >300 copies/mL in plasma, the 2 assays are comparable for CMV detection, although they return lower CMV load measurements (Atkinson, unpublished data). CMV loads were measured in all specimens for each infant up to 12 months of age. The lower limit of detection was 100 copies/mL. Infants with no detection of CMV DNA throughout follow-up underwent serologic testing of their last-collected plasma specimen closest to 12 months of age, to determine final infection status; only plasma specimens collected beyond 6 months of age were included for serologic analysis, to avoid confounding by maternal antibodies. Enzyme-linked immunosorbent assay (ELISA) was used to detect a panel of antibodies targeting CMV immunoglobulin G (CMV ELISA II test kit Wampole Laboratories, Princeton, New Jersey). All analyses were intent-to-treat and were performed using SPSS, version 20.0 (IBM). Baseline characteristics for infants included in the CMV analyses were compared between randomization arms using Mann–Whitney U tests (for continuous variables) and χ2 tests (for categorical variables). HIV-exposed uninfected infants were defined as infants with their last CMV test at or after their last HIV-negative test and who never had HIV infection diagnosed. The proportion of infants infected with CMV at birth were compared between arms using Fisher’s exact test; the proportion with CMV DNA detection and the proportion with CMV antibody detection were compared between arms using Pearson χ2 tests. Time to CMV infection was compared between arms using Kaplan–Meier curves and the log-rank test. z tests were used to compare median time to CMV infection and the probability of CMV infection at 1 year. Cox proportional hazards models were used to assess the independent effects of time-varying HIV infection status and feeding modality, as well as any potential effect modification of these 2 variables on CMV acquisition. In addition to the intent-to-treat analyses described above, all analyses were performed categorizing infants as breastfed or formula fed, based on the mother’s self-reported feeding history. For these analyses, infants whose mothers ever reported breastfeeding were classified as breastfed, and infants whose mothers never reported breastfeeding were classified as formula fed. Estimates of the proportion of CMV infections attributable to different modes of transmission in the first year of life were obtained by comparing the proportions of infants with CMV DNA detection in the breastfed and formula-fed infants at defined time points. Because of interval sampling at delivery and 6 weeks of age, we were unable to discriminate in utero from intrapartum infections; we thus combined infections detected at ≤6 weeks of age as “peripartum” transmissions, which are presumed to primarily include in utero and intrapartum and potentially very early breast milk or saliva transmissions. Infections due to saliva and/or urine exposure were defined as those infections occurring after 6 weeks of age in the formula-fed infants, and infections due to breast milk exposure were defined as the excess infections between the breastfed and formula-fed infants at 1 year of age. Because 30% of the women randomly assigned to the formula-feeding arm elected to breastfeed [22], this analysis was conducted as as-treated.

N/A

Based on the information provided, it appears that the study focused on the impact of breastfeeding on the transmission of cytomegalovirus (CMV) from HIV-infected mothers to their infants. The study found that breastfeeding was associated with a higher risk of CMV acquisition in infants compared to formula feeding. The study also highlighted the importance of interventions to reduce CMV reactivation in mothers to delay infant infection.

Based on this information, here are some potential recommendations for innovations to improve access to maternal health and address the issue of CMV transmission:

1. Education and awareness programs: Develop educational materials and campaigns to raise awareness among HIV-infected mothers about the risks of CMV transmission through breastfeeding. Provide information on alternative feeding options and the importance of safe infant feeding practices.

2. Antiretroviral therapy (ART) for prevention of mother-to-child HIV transmission (PMTCT): Ensure that HIV-infected mothers have access to ART to reduce the risk of HIV transmission to their infants. This can help reduce the need for breastfeeding and potentially decrease CMV transmission as well.

3. Improved CMV testing and monitoring: Develop more sensitive and accessible testing methods for CMV in infants and mothers. This can help identify CMV infections early and enable timely interventions to prevent further transmission.

4. Support for formula feeding: Provide support and resources for HIV-infected mothers who choose to formula feed their infants. This can include access to safe and affordable formula, counseling on proper formula preparation and feeding practices, and ongoing support from healthcare professionals.

5. Research on interventions to reduce CMV reactivation: Conduct further research to identify interventions that can reduce CMV reactivation in HIV-infected mothers. This can include exploring antiviral medications or other strategies to suppress CMV replication and decrease the risk of transmission.

6. Integration of maternal health services: Ensure that maternal health services, including HIV care and CMV prevention, are integrated and easily accessible to HIV-infected mothers. This can improve coordination of care and increase the likelihood of successful interventions.

It’s important to note that these recommendations are based on the information provided and may need to be further evaluated and tailored to specific contexts and populations.
AI Innovations Description
Based on the provided description, the recommendation to improve access to maternal health and prevent vertical cytomegalovirus (CMV) transmission from HIV-infected mothers to their infants is to focus on reducing maternal cervical and breast milk CMV reactivation. This can help delay infant CMV infection and improve overall maternal and infant health outcomes.

To develop this recommendation into an innovation, the following steps can be taken:

1. Research and Development: Conduct further research to understand the mechanisms of CMV reactivation in HIV-infected mothers and identify potential interventions to reduce reactivation. This may involve studying the impact of antiretroviral therapy (ART) on CMV reactivation and exploring other preventive measures.

2. Intervention Development: Based on the research findings, develop interventions that specifically target CMV reactivation in HIV-infected mothers. This may include developing medications or treatments that can suppress CMV reactivation or boost the immune response against CMV.

3. Implementation and Training: Implement the developed interventions in healthcare settings where HIV-infected mothers receive prenatal and postnatal care. Provide training to healthcare providers on the use of the interventions and ensure proper implementation to maximize their effectiveness.

4. Monitoring and Evaluation: Continuously monitor the impact of the interventions on reducing CMV reactivation and vertical transmission. Evaluate the effectiveness of the interventions in improving maternal and infant health outcomes, such as reducing infant CMV infections and associated morbidity and mortality.

5. Scaling Up and Sustainability: If the interventions prove to be effective, work towards scaling up their implementation to reach a larger population of HIV-infected mothers. Collaborate with relevant stakeholders, such as government agencies, non-profit organizations, and international health organizations, to ensure the sustainability of the interventions and their integration into existing maternal health programs.

By focusing on reducing CMV reactivation in HIV-infected mothers, this innovation can contribute to improving access to maternal health and reducing the risk of vertical CMV transmission, ultimately leading to better health outcomes for both mothers and infants.
AI Innovations Methodology
Based on the provided information, here are some potential recommendations for improving access to maternal health:

1. Increase awareness and education: Implement comprehensive education programs to raise awareness about the importance of maternal health and the risks associated with certain practices, such as breastfeeding in the case of HIV-infected mothers. This can be done through community outreach, antenatal care sessions, and media campaigns.

2. Strengthen healthcare infrastructure: Improve the availability and quality of healthcare facilities, especially in rural areas where access to maternal health services may be limited. This includes ensuring the presence of skilled healthcare providers, necessary medical equipment, and essential medications.

3. Enhance antenatal care services: Focus on early detection and management of potential health risks during pregnancy. This can involve regular check-ups, screenings, and appropriate interventions to address any complications or infections that may affect maternal and infant health.

4. Promote alternative feeding options: Provide support and resources for HIV-infected mothers to safely and effectively formula-feed their infants. This can include access to clean water, proper formula preparation training, and financial assistance to cover the cost of formula.

To simulate the impact of these recommendations on improving access to maternal health, a methodology could be developed as follows:

1. Define the indicators: Identify specific indicators that measure access to maternal health, such as the percentage of pregnant women receiving antenatal care, the availability of healthcare facilities in rural areas, or the percentage of HIV-infected mothers opting for formula feeding.

2. Collect baseline data: Gather data on the current status of these indicators before implementing the recommendations. This can be done through surveys, interviews, or existing data sources.

3. Implement interventions: Roll out the recommended interventions in the target population. This could involve implementing education programs, improving healthcare infrastructure, and providing support for alternative feeding options.

4. Monitor and evaluate: Continuously monitor the progress and impact of the interventions. Collect data on the selected indicators at regular intervals to assess any changes or improvements. This can be done through surveys, interviews, or data collection from healthcare facilities.

5. Analyze the data: Use statistical analysis techniques to analyze the collected data and determine the impact of the interventions on access to maternal health. This could involve comparing the baseline data with the post-intervention data to identify any significant changes or improvements.

6. Draw conclusions and make recommendations: Based on the analysis, draw conclusions about the effectiveness of the interventions in improving access to maternal health. Identify any gaps or areas for further improvement and make recommendations for future interventions or policies.

7. Iterate and refine: Use the findings from the evaluation to refine and improve the interventions. Continuously iterate and adapt the strategies based on the data and feedback received to ensure ongoing improvement in access to maternal health.

It is important to note that the specific methodology and data collection techniques may vary depending on the context and resources available.

Share this:
Facebook
Twitter
LinkedIn
WhatsApp
Email